Paper39477378
Molecular Hydrogen Therapy in Sjögren's Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell.
Lin YT and 6 others. In Vivo, 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Molecular Hydrogen Therapy in Sjögren's Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell. Papers, record 39477378. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39477378
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular Hydrogen Therapy in Sjögren's Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sjogren's Syndrome | Major topic |
| Heart Failure | Major topic |
| Hydrogen | Major topic |
| Pulmonary Arterial Hypertension | Major topic |
| T-Lymphocytes, Regulatory | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| B-Lymphocytes | |
| Biomarkers | |
| Treatment Outcome |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38688598 | Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report. | In Vivo | 2024 | https://conductscience.org/library/papers/38688598 | PubMed |
| 2 | 38107500 | Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial. | Ther Clin Risk Manag | 2023 | https://conductscience.org/library/papers/38107500 | PubMed |
| 3 | 35187885 | Molecular hydrogen is a promising therapeutic agent for pulmonary disease. | J Zhejiang Univ Sci B | 2022 | https://conductscience.org/library/papers/35187885 | PubMed |
| 4 | 38795643 | Potential role of molecular hydrogen therapy on oxidative stress and redox signaling in chronic kidney disease. | Biomed Pharmacother | 2024 | https://conductscience.org/library/papers/38795643 | PubMed |
| 5 | 36624795 | Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia. | JACC Asia | 2022 | https://conductscience.org/library/papers/36624795 | PubMed |
| 6 | 35883781 | Coral Hydrate, a Novel Antioxidant, Improves Alcohol Intoxication in Mice. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/35883781 | PubMed |
| 7 | 34100160 | Sjögren's syndrome: a systemic autoimmune disease. | Clin Exp Med | 2022 | https://conductscience.org/library/papers/34100160 | PubMed |
| 8 | 38067515 | Molecular Hydrogen Therapy-A Review on Clinical Studies and Outcomes. | Molecules | 2023 | https://conductscience.org/library/papers/38067515 | PubMed |
| 9 | 33095142 | Interstitial lung disease in Sjögren's syndrome: a clinical review. | Clin Exp Rheumatol | 2020 | https://conductscience.org/library/papers/33095142 | PubMed |
| 10 | 21687512 | Hydrogen Therapy may be a Novel and Effective Treatment for COPD. | Front Pharmacol | 2011 | https://conductscience.org/library/papers/21687512 | PubMed |
| 11 | 23829793 | Pulmonary arterial hypertension. | Orphanet J Rare Dis | 2013 | https://conductscience.org/library/papers/23829793 | PubMed |
| 12 | 35250621 | Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer. | Front Physiol | 2022 | https://conductscience.org/library/papers/35250621 | PubMed |
| 13 | 38929185 | A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease. | Antioxidants (Basel) | 2024 | https://conductscience.org/library/papers/38929185 | PubMed |
| 14 | 38088955 | Connective tissue disease-associated pulmonary hypertension: A comprehensive review. | Pulm Circ | 2023 | https://conductscience.org/library/papers/38088955 | PubMed |
| 15 | 28610655 | The Diagnosis and Treatment of Sjögren's Syndrome. | Dtsch Arztebl Int | 2017 | https://conductscience.org/library/papers/28610655 | PubMed |
| 16 | 37652509 | Using Treg, Tr1, and Breg Expression Levels to Predict Clinical Responses to csDMARD Treatment in Drug-naive Patients With Rheumatoid Arthritis. | In Vivo | 2023 | https://conductscience.org/library/papers/37652509 | PubMed |
| 17 | 24355643 | Updated treatment algorithm of pulmonary arterial hypertension. | J Am Coll Cardiol | 2013 | https://conductscience.org/library/papers/24355643 | PubMed |
| 18 | 26320113 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). | Eur Heart J | 2016 | https://conductscience.org/library/papers/26320113 | PubMed |
| 19 | 17376507 | Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. | Hum Pathol | 2007 | https://conductscience.org/library/papers/17376507 | PubMed |
| 20 | 37439387 | Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets. | APMIS | 2023 | https://conductscience.org/library/papers/37439387 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957267 | Sustained Tocilizumab and Adjunctive HydroBox Therapy in Refractory Takayasu Arteritis: An 11-year Case Report. | In Vivo | 2026 | https://conductscience.org/library/papers/42957267 | PubMed |
| 42668873 | Research Progress of Molecular H2 in Mediating Immune Tolerance via Regulating Tregs-from the Perspective of the 2025 Nobel Prize in Physiology or Medicine. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42668873 | PubMed |
| 42379742 | Molecular Hydrogen Reverses Sepsis-induced Immunoparalysis: Insights from Longitudinal Deep Immunophenotyping. | In Vivo | 2026 | https://conductscience.org/library/papers/42379742 | PubMed |
| 42255997 | Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren's syndrome-associated interstitial lung disease: A case report. | SAGE Open Med Case Rep | 2026 | https://conductscience.org/library/papers/42255997 | PubMed |
| 42164762 | A narrative review of hydrogen therapy for COPD: aging-related insights. | Open Med (Wars) | 2026 | https://conductscience.org/library/papers/42164762 | PubMed |
| 41760342 | Adjunctive Molecular Hydrogen Therapy Modulates T Cell Markers and Reduces Anti-Ro Antibody in Refractory Oral Ulcers of Behçet's Disease and Sjögren's Syndrome: A Case Report. | In Vivo | 2026 | https://conductscience.org/library/papers/41760342 | PubMed |
| 41482418 | Longitudinal Immune Profiling of T Cell Exhaustion During IL-17A Blockade in a Patient With HLA-B27-negative Spondyloarthritis and Sjögren's Syndrome: A Case Report. | In Vivo | 2026 | https://conductscience.org/library/papers/41482418 | PubMed |
| 41482388 | Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes. | In Vivo | 2026 | https://conductscience.org/library/papers/41482388 | PubMed |
| 41254431 | H2 as a potential redox homeostasis modulator: a review of mechanisms targeting key elements of cardiovascular pathogenesis-related pathways. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/41254431 | PubMed |
| 40877145 | Immunomodulatory Effects of Molecular Hydrogen Therapy in Systemic Lupus Erythematosus With Pericarditis and Pleuritis: A Case Report. | In Vivo | 2025 | https://conductscience.org/library/papers/40877145 | PubMed |
| 40579028 | Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation. | In Vivo | 2025 | https://conductscience.org/library/papers/40579028 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IL7R | 3575 | PubTator's text mining | https://conductscience.org/library/genes/3575 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39477378
GET https://conductscience.org/api/papers/v1/39477378/references?page=2